UNITED STATES SECURITIES AND EXCHANGE COMMISSION ~~WASHINGTON~~ Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934

~~PURSUANT~~September TO3, ~~SECTION~~2013 13Date ORof ~~15(d)~~Report ~~OF THE~~(Date ~~SECURITIES~~of ~~EXCHANGE~~earliest ~~ACT~~event OFreported) ~~1934~~

~~August~~FIRST ~~21,~~CHINA ~~2012~~PHARMACEUTICAL GROUP, INC. ~~Date~~(Exact Name of ~~Report~~Registrant ~~(Date~~as ofSpecified ~~earliest~~in ~~event reported~~Charter)

First China Pharmaceutical Group, Inc. (Exact Name of Registrant as Specified in Charter)

Nevada	000-54076	74-3232809
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Number 504, West Ren Min Road, Kunming City, Yunnan Province People’s Republic of China, 650000 (Address of Principal Executive Offices)

852-2138-1668 (Registrant’s telephone number, including area code) (Former Name or Former Address, if Changed Since Last Report.) \

_____________________________________________ (Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

[ ] Soliciting material pursuant to Rule 14a-12 ~~Section~~under 2the –Exchange ~~Financial~~Act ~~Information~~(17 CFR 240.14a -12)

~~Item~~[ ] Pre-commencement communications pursuant to Rule 14d-2~~.02.~~(b) ~~Results~~under ofthe ~~Operations~~Exchange ~~and~~Act ~~Financial~~(17 ~~Condition~~CFR 240.14d -2(b))

On[ ] ~~August~~Pre-commencement ~~21,~~communications ~~2012,~~pursuant ~~First~~to Rule ~~China Pharmaceutical Group, Inc., a Nevada corporation~~ 13e-4(~~the “Company”~~c) ~~issued~~under ~~a press release reporting its financial results for~~ the ~~quarter~~Exchange ~~ended~~Act ~~June~~(17 ~~30,~~CFR ~~2012~~240.13e -4(c))

ASECTION ~~copy~~4 of- ~~the~~MATTERS ~~press~~RELATED ~~release~~TO isACCOUNTANTS ~~attached~~AND ~~hereto~~FINANCIAL STATEMENTS ~~as Exhibit 99.1 and incorporated herein by reference.~~

~~Section~~Item 94.01. –Changes ~~Financial~~in ~~Statements~~Registrant’s ~~and~~Certifying ~~Exhibits~~ Accountant.

Effective September 3, 2013, EFP Rotenberg LLP (“EFP”) resigned as the independent registered public accounting firm of First China Pharmaceutical Group, Inc. (the “Company”). The Company’s Board of Directors informed EFP that it would not accept their resignation.

EFP maintains that it resigned due to an outstanding amount of $40,000 relating to its audit of the Company’s financial statements for the fiscal year ended December 31, 2012 (the “2012 Audit”). However, the Company previously on August 6, 2013 offered to pay the $40,000 to EFP in advance of completion of the 2012 Audit if a memorandum of understanding was signed and sent to the Company. EFP ignored this communication as well as other communications from the Company. The Company also requested EFP’s reassurance in writing that if all payments are made, the 2012 Audit and related filings will be made. The Company made this request because of EFP’s unresponsive behavior to the Company’s attempts to finalize the memorandum of understanding. EFP has not provided the written confirmation requested by the Company or responded to the Company’s efforts to negotiate a memorandum of understanding.

The reports of EFP regarding the Company’s financial statements for the nine months ended December 31, 2011 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. EFP did not issue a report regarding the Company’s financial statements for the fiscal year ended December 31, 2012.

During the nine months ended December 31, 2011, and during the period from January 16, 2012 through September 3, 2013, the date of dismissal, (i) there were no disagreements with EFP on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of EFP would have caused it to make reference to such disagreement in its reports; and (ii) there were no reportable events as defined in Item 304(a)(1)(v) of Regulation S-K.

The Company has provided EFP with a copy of the foregoing disclosures and requested that EFP furnish the Company with a letter addressed to the SEC stating whether or not it agrees with the above statements, and if not, stating the respects in which it does not agree. A copy of such letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.

SECTION 9 - FINANCIAL STATEMENTS AND EXHIBITS

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Exhibit Description
	Exhibit
99.1	Press Release dated August 21, 2012
	Number	Description
	16.1	Letter from EFP Rotenberg LLP, dated September 10, 2013

The information set forth under Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934 or the Securities Act of 1933, whether made before or after the date hereof and irrespective of any general incorporation by reference language in any filing.

Portions of this report constitute “forward-looking statements” defined by federal law. Although the Company believes any such statements are based on reasonable assumptions, there is no assurance that the actual outcomes will not be materially different. Any such statements are made in reliance on the “safe harbor” protections provided under the Private Securities Litigation Reform Act of 1995. Additional information about issues that could lead to material changes in the Company’s performance is contained in the Company’s filings with the Securities and Exchange Commission and may be accessed at www.sec.gov.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

First China Pharmaceutical Group, Inc.

Dated: August 22, 2012

Dated: September 13, 2013	By:	/s/ Zhen Jiang Wang

		Zhen Jiang Wang
		Chief Executive Officer

By: /s/ Zhen Jiang Wang Zhen Jiang Wang Chief Executive Officer

Filing Compare · FIRST CHINA PHARMACEUTICAL GROUP, INC.